Metra gets Japanese reimbursement for bone test:
This article was originally published in Clinica
Japan's Ministry of Health and Welfare has agreed to reimburse Metra Biosystems' Osteolinks-DPD bone resorption test. The test, which will be marketed by Sumitomo Pharmaceuticals, is the first product to be launched by Metra in Japan. California-based Metra says that Bayer and Abbott will both launch assays using its DPD technology in the near future.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.